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There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes
to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading
enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE), and
angiotensin-converting enzyme (ACE) reduce Aβ levels and protect against cognitive
impairment in mouse models of AD. In post-mortem human brain tissue we have found
that the activity of these Aβ-degrading enzymes rise with age and increases still further
in AD, perhaps as a physiological response that helps to minimize the build-up of Aβ.
ECE-1/-2 and ACE are also rate-limiting enzymes in the production of endothelin-1 (ET-1)
and angiotensin II (Ang II), two potent vasoconstrictors, increases in the levels of which
are likely to contribute to reduced blood flow in AD. This review considers the possible
interdependence between Aβ-degrading enzymes, ischemia and Aβ in AD: ischemia has
been shown to increase Aβ production both in vitro and in vivo, whereas increased Aβ
probably enhances ischemia by vasoconstriction, mediated at least in part by increased
ECE and ACE activity. In contrast, NEP activity may help to maintain cerebral perfusion,
by reducing the accumulation of Aβ in cerebral blood vessels and lessening its toxicity
to vascular smooth muscle cells. In assessing the role of Aβ-degrading proteases in the
pathogenesis of AD and, particularly, their potential as therapeutic agents, it is important
to bear in mind the multifunctional nature of these enzymes and to consider their effects
on other substrates and pathways.
Keywords: endothelin-1, angiotensin-converting enzyme, neprilysin, cerebral hypoperfusion, cerebral amyloid
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INTRODUCTION
The accumulation of Aβ within the brain is central to the
pathogenesis of AD. The level of Aβ depends not only on its
rate of production but also on the rate of its removal via
various clearance pathways including enzyme-mediated degra-
dation. Mice with inactivation of the Mme (neprilysin, mem-
brane metalloendopeptidase), Mmel1 (neprilysin-2, membrane
metalloendopeptidase-like 1), Ide, Ece1, or Ece2 gene, all have
a modest (1.5–2-fold) increase in Aβ levels. Overexpression
of the human orthologs of these genes in transgenic mice
expressing mutant forms of human amyloid-β precursor pro-
tein (hAPP) that cause familial AD, reduce Aβ accumulation
and in most, but not all cases, improves motor and cogni-
tive performance. Findings from large post-mortem human
brain studies and in vitro experiments have, however, revealed
that the level and activity of many Aβ-degrading proteases are
increased in post-mortem brain tissue and are upregulated by
Aβ, suggesting that the increases are secondary to Aβ accu-
mulation, possibly representing physiological responses to the
rise in concentration of substrate. Many of the Aβ-degrading
enzymes are involved in other physiological systems. For exam-
ple, ECE-1/-2 and ACE are rate-limiting enzymes in the pro-
duction of ET-1 and Ang II, respectively. In this review we
discuss the balance between beneficial and potential deleterious
effects of upregulating these vasoactive enzyme systems, and the
broader relationships between Aβ and cerebral perfusion in the
context of AD.
Aβ PRODUCTION AND CLEARANCE IN ALZHEIMER’S
DISEASE
Amyloidogenic processing of APP to produce Aβ peptides results
from the sequential actions of β- and γ-secretase (Selkoe, 2001;
Evin and Weidemann, 2002; Mattson, 2004), yielding mostly
Aβ1−40 and a lesser amount of Aβ1−42. Increased produc-
tion of the less soluble Aβ1−42, or an increase in the ratio of
Aβ1−42:Aβ1−40, is hypothesized to initiate a cascade of patho-
logical processes leading to the development of AD (Hardy,
1997). According to the somewhat simplified view of the devel-
opment of the hallmark pathological lesions of AD, extracellular
Aβ1−42, which is more prone to aggregate (Jarrett et al., 1993)
and more toxic than Aβ1−40, precipitates as “plaques” within the
brain parenchyma and induces the development of neuritic and
neurofibrillary tangle pathology, whereas much of the relatively
soluble, less toxic Aβ1−40 reaches the cerebral blood vessels where
some of it may precipitate, leading to cerebral amyloid angiopathy
(CAA).
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In all forms of AD, the level of Aβ in the brain is a reflection
of the relative rates of Aβ production and clearance over time.
In healthy individuals, the production and clearance of Aβ are
rapid (estimated at∼7.6% and 8.3%, respectively, of the total vol-
ume of Aβ produced per hour (Bateman et al., 2006; Mawuenyega
et al., 2010). These data suggest that even very small changes
in the production or clearance of Aβ would soon cause abnor-
mal accumulation in AD. Early-onset familial AD usually results
from autosomal dominant mutations in the genes encoding APP
(APP), presenilin-1 (PSEN1) or presenilin-2 (PSEN2) (reviewed
in Tanzi and Bertram, 2005). These mutations alter the process-
ing of APP, increasing the ratio of Aβ1−42:Aβ1−40 (Scheuner et al.,
1996; Price et al., 1998). Early-onset AD can also be caused by
increased production of APP, in trisomy-21 (Belza and Urich,
1986; Donahue et al., 1998), or duplication in the APP locus on
chromosome 21 (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006).
In sporadic AD (i.e., in over 90% of cases) there is less com-
pelling evidence that increased amyloidogenic processing of APP
is responsible for Aβ accumulation. Although studies on human
post-mortem brain tissue reported increased β- and γ-secretase
activities in sporadic AD (Tyler et al., 2002; Stockley et al., 2006;
Miners et al., 2010a), studies in two strains of mouse transgenic
for hAPP (one causing early and one causing late accumulation
of Aβ) found that β-secretase activity increased only after the
development of Aβ plaques (Zhao et al., 2007).
Over the last fifteen years, many studies have focused on pos-
sible abnormalities of clearance of Aβ in late-onset sporadic AD,
and reported age- and disease-related deficiencies in numerous
clearance pathways, including reductions in Aβ-degrading pro-
tease activities. Soluble Aβ is cleared from the brain by multiple,
diverse pathways including drainage along perivascular basement
membranes (Weller et al., 1998, 2000; Preston et al., 2003) and
receptor-mediated transport of Aβ across the blood-brain barrier
[including transport mediated by binding to low-density lipopro-
tein receptor-related protein (LRP-1) (Shibata et al., 2000) and
through the activity of P-glycoprotein efflux pump (Lam et al.,
2001; Vogelgesang et al., 2002; Kuhnke et al., 2007)]. For an in-
depth review of pathways which mediate Aβ clearance, see Bell
et al. (2007).
Multiple proteolytic enzymes have been identified that cleave
Aβ at single or multiple sites (for comprehensive reviews, see
Carson and Turner, 2002; Eckman and Eckman, 2005;Wang et al.,
2006; Bell et al., 2007; Miners et al., 2011a; Nalivaeva et al., 2012).
Amongst the enzymes that cleave Aβ in vitro are a number of zinc
metalloendopeptidases including neprilysin (NEP), angiotensin-
converting enzyme (ACE), and endothelin-converting enzyme-1
and -2 (ECE); thiol-metalloendopeptidases including insulin-
degrading enzyme (IDE), matrix metalloproteinases [MMP-2, -9
and type-1 transmembrane MMP (MT1-MMP)]; serine pro-
teases including myelin-basic protein (MBP), plasminogen and
acyl peptide hydrolase (APEH), and cysteine proteases such as
cathepsin B (for a more detailed description, refer to Miners et al.,
2011a). Fragments of Aβ produced by proteolytic cleavage in vitro
are generally considered to be less neurotoxic, and less likely to
aggregate (and therefore predicted to be more easily cleared from
the brain) (Mukherjee et al., 2000; Hu et al., 2001). Mice with
inactivation of Mme (Iwata et al., 2001), Mmel1 (Hafez et al.,
2011), Ece1, Ece2 (Eckman et al., 2003), or Ide (Farris et al., 2003;
Miller et al., 2003) genes all have a moderate (1.5–2-fold) increase
in endogenous Aβ. These KO mice did not display pathologi-
cal deposition of endogenous Aβ compared to mice infused with
thiorphan (Iwata et al., 2000), or phosphoramidon (Nisemblat
et al., 2008), which probably reflects the overlapping substrate
specificity of these inhibitors for multiple Aβ-degrading enzymes.
Inactivation of NEP in hAPP mice was associated with impaired
synaptic plasticity and cognitive performance (Huang et al., 2006)
and was sufficient to cause plaque-like pathology (Farris et al.,
2007). Conversely, overexpression of NEP (resulting in an 8- and
30-fold increase in protein level and enzyme activity, respectively)
in hAPP transgenic (Swe/Ind) mice markedly reduced cerebral Aβ
load, reversed pathological abnormalities, and improved cogni-
tive performance and survival (Leissring et al., 2003; Poirier et al.,
2006). Several other experimental strategies, aimed at increas-
ing NEP within the CNS, by targeting either the CNS directly,
or via the periphery, have suggested that upregulation of NEP
might be used to treat AD (Iwata, 2003; Marr et al., 2003, 2004;
El-Amouri et al., 2008; Spencer et al., 2008, 2011; Briyal et al.,
2011). Induction of peripherally expressed NEP was reported to
regulate Aβ level within the CNS perhaps by reducing plasma Aβ
(Guan et al., 2009; Liu et al., 2009) but this, and the peripheral-
sink hypothesis, has been refuted in recent studies (Walker et al.,
2013; Henderson et al., 2014).
Earlier studies on human post-mortem brain tissue presented
evidence to support the hypothesis that an age- and disease-
related deficit in Aβ-degrading protease activity contributes to Aβ
accumulation, particularly in late-onset AD. The studies reported
reduced NEP and IDE mRNA levels and protein immunolabeling
in AD compared to control brains (Akiyama et al., 2001; Yasojima
et al., 2001; Russo et al., 2005; Miners et al., 2006; Hellstrom-
Lindahl et al., 2008). However, they did not measure enzyme
activity, the most relevant biological measure with respect to Aβ
metabolism, were mostly based on small cohorts, in many cases
did not adjust for neuronal content, and showed poor correla-
tion between different methodologies (Russo et al., 2005; Miners
et al., 2006; Hellstrom-Lindahl et al., 2008). We developed ELISA
and immunocapture-based fluorogenic activity assays to measure
the levels and/or specific enzyme activities of NEP, IDE, ECE-1,
ECE-2, and ACE within biological tissue samples, including CSF,
plasma, brain tissue homogenates and blood vessel preparations
(Miners et al., 2008a,b), and used the concentration of neuron-
specific enolase to adjust for neuronal content (Miners et al.,
2009) in the case of NEP, IDE, ACE and ECE-2, and the concen-
tration of factor VIII-related antigen to adjust for the endothelial
cell content in the case of ECE-1 (Palmer et al., 2010). Contrary
to our expectation, in a large series of well-characterized human
post-mortem brains, we found that NEP, IDE, ACE, and ECE-1
activities and ECE-2 levels were all higher in AD than in age-
matched controls (Miners et al., 2008c, 2009, 2010b; Palmer et al.,
2009, 2010) and rose progressively with disease severity, as indi-
cated by Braak tangle stage. The increase in the level and activity
of NEP, IDE, and ACE was particularly pronounced after adjust-
ment for neuronal loss in AD, and was directly related to the
Braak tangle stage. Levels and activities of ACE and NEP were also
elevated and correlated positively with Aβ1−42 level in Down’s
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syndrome, which is associated with the development of AD-type
neuropathology (Miners et al., 2011b). NEP, IDE, and ACE levels
tended to rise with normal aging and were further increased in
AD (Miners et al., 2010a). Other groups reported that other can-
didate Aβ-degrading proteases, including MMP-2 -3 and -9 (Yan
et al., 2006; Bruno et al., 2009), cathepsin D (Gan et al., 2004;
Mueller-Steiner et al., 2006; Sundelof et al., 2010) and APEH
(Yamin et al., 2009), were also increased in human post-mortem
brain tissue in AD, in most but not all studies (Baig et al., 2008;
Barker et al., 2010). It should be noted we examined only the
mid-frontal cortex, an area with a similar level of Aβ pathology to
that in the temporal cortex (and more than that in the hippocam-
pus) but affected by tau pathology only later in disease, and our
approach did not take into account the relative contribution of
various different cell types to overall NEP activity, an important
topic for future research (see review by Saido, 2013).
Nevertheless, there is evidence to suggest that proteolysis of Aβ
is not deficient in AD. On the contrary, our findings in human
post-mortem tissue indicate that Aβ-degrading activity correlates
positively with Aβ concentration, as would be expected for a phys-
iological response to increasing substrate. This is supported by
a large number of cell culture studies showing that exposure of
neuronal, glial and vascular cell lines to Aβ (particularly fibril-
lar Aβ) upregulates multiple Aβ-degrading proteases including
NEP, ECE, ACE, ECE-2, IDE, MMP-2 -3 and -9 (Deb et al., 1999;
Jung et al., 2003; Lee et al., 2003; Leal et al., 2006; Palmer et al.,
2009; Wang et al., 2009a,b; Miners et al., 2010b). A number of
studies have reported a rise in Aβ-degrading protease activity in
aged hAPP transgenic mice, coinciding with the appearance of
parenchymal deposits of Aβ (Tucker et al., 2000; Leal et al., 2006;
Yin et al., 2006). A dose-dependent increase in NEP was also
observed in hAPP mice following intracerebral injection of syn-
thetic fibrillar Aβ (Mohajeri et al., 2002, 2004). Together, these
data suggest that Aβ-mediated upregulation of protease activity is
secondary to Aβ accumulation in late-onset AD and that Aβ accu-
mulates in association with a failed compensatory response rather
than an overall deficiency in Aβ-degrading enzyme activity. Even
if this is the case it does not preclude the potential of enhancing
or administering Aβ-degrading proteases as a therapeutic target
for AD. However, whilst upregulation of Aβ-degrading enzymes
probably slows the accumulation of Aβ, it may also increase the
cleavage of other substrates of these multifunctional enzymes.
Those substrates include several peptides that play important
roles in regulating cerebral blood flow.
THE ENDOTHELIN SYSTEM IN ALZHEIMER’S DISEASE
Endothelin-1 (ET-1) is a potent, long-lasting vasoconstrictor in
the brain (Haynes and Webb, 1994). It is produced predom-
inantly by vascular endothelial cells, but also by neurons and
macrophages in human brain tissue (Palmer et al., 2012). ET-1
is generated from the inactive precursor, big-ET-1, through cleav-
age by ECE-1 or -2 (Yanagisawa et al., 2000). ECE-1 is expressed
predominantly within the cerebral vasculature within endothelial
cells (Palmer et al., 2010) but is also expressed by smooth muscle
cells (Maguire, 2002), and weak neuronal and astrocytic stain-
ing of ECE-1 was observed in human brain tissue (Palmer et al.,
2010). ECE-2 is expressed by pyramidal neurons, and to a lesser
extent glia, within the neocortex (Palmer et al., 2009), including
cells in close association with blood vessels. ET-1 has potent and
sustained vasoconstrictor effects both in vitro and in vivo (Brain
et al., 1988; Yanagisawa et al., 1988; Borges et al., 1989; Brain,
1989). Chronic infusion of ET-1 in to Sprague–Dawley rats led
to sustained elevation inmean arterial blood pressure (Mortensen
et al., 1990) and reduced perfusion, with subsequent neuronal loss
(Hughes et al., 2003).
There is dysregulation of the endothelin system in AD. Several
studies have shown that the concentration of ET-1 is higher in
AD than controls in both the cerebral cortex (Minami et al.,
1995; Palmer et al., 2012) and in cerebral blood vessels (Luo
and Grammas, 2010; Palmer et al., 2013). ECE-1 and ECE-2
degrade Aβ (Eckman et al., 2001), and ECE-1 heterozygous and
ECE-2 homozygous knockout mice display significantly elevated
endogenous Aβ1−40 and Aβ1−42 (Eckman et al., 2001, 2003).
However, we found ECE-2 level and ECE-1 activity (Palmer et al.,
2009, 2010, 2013) to be higher in AD than in age-matched con-
trols, in human post-mortem cerebral cortex and leptomeninges.
We did not observe similar elevations in post-mortem tissue from
patients with vascular dementia (VaD).
Upregulation of ET-1 production in AD seems likely to be
secondary to the accumulation of Aβ, since exposure of SH-
SY5Y human neuroblastoma cells and human brain microvas-
cular endothelial cells to Aβ caused upregulation of ECE-2 and
ECE-1, respectively, resulting in increased production and release
into the supernatant of ET-1 (Palmer et al., 2009, 2012, 2013). ET-
1 production was also elevated in the cerebral vasculature of mice
that had been infused with Aβ (Paris et al., 2003). The authors
also showed that Aβ enhanced ET-1 induced vasoconstriction
in isolated human middle cerebral and basilar arteries. Mice
that overexpress hAPP showed no diminution in the contractile
response of cerebral vessels to ET-1, despite an impaired response
to vasodilators (Tong et al., 2005). Together, these studies sug-
gest that upregulation of ECE-1 and -2 is a physiological feedback
response to Aβ that probably increases degradation of Aβ and
reduces its further accumulation but also results in increased
production and release of ET-1 which mediates vasoconstriction
(reviewed in Palmer and Love, 2011) (Figure 1).
It should be noted that hypoxia itself can upregulate com-
ponents of the ET system. The EDN1 gene contains a HIF1-α
binding site (Takanashi et al., 2004) and ET-1 expression is
induced by hypoxia or ischemia (Li et al., 1994; Yamashita et al.,
2001; Ao et al., 2002; Kang et al., 2011). In another study, ECE-1
protein level and ETA and ETB receptor expression were increased
in response to hypoxia both in vitro and in vivo (Li et al., 1994;
Kang et al., 2011). Furthermore, ET-1 was shown to induce HIF1-
α expression dose-dependently in cultured pulmonary smooth
muscle cells (Li et al., 2012). Upregulation of more than one path-
way may therefore account for increased production of ET-1 in
dementia, including in AD.
ETA receptor antagonists, but not dual ETA/ETB receptor
antagonists significantly reduced the impairment in learning and
memory induced by Aβ in rats (Briyal et al., 2011), as well as
preventing the Aβ-induced increase in expression of ETA recep-
tors and oxidative stress. Additionally, an ETB receptor agonist
elevated CBF in normal rats and acted as an anti-apoptotic
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FIGURE 1 | Divergent roles of Aβ-degrading enzymes in the
pathogenesis of AD. (1) ECE-1/-2 and ACE cleave Aβ in vitro and ECE-1/-2
regulate endogenous Aβ level in mice. However, ECE-1/-2 and ACE
activities are increased in the cerebral cortex in AD in human post-mortem
brain tissue. The increases are likely to represent responses to
accumulating Aβ and may mitigate the accumulation but are inadequate to
prevent the level of Aβ from continuing to rise as the disease progresses.
(2) Upregulation of ECE-1/2 and ACE by Aβ results in increased production
of ET-1 and Ang II, both of which mediate vasoconstriction. (3) Reduced
cerebral perfusion, as a result of vasoconstriction, probably increases Aβ
production by promoting amyloidogenic processing of APP. (4) NEP protects
vessels from Aβ-related pathology, including CAA, but NEP activity is
reduced in conditions of hypoxia and oxidative stress.
factor, counteracting the neurotoxicity and cognitive impair-
ment induced by Aβ (Briyal et al., 2014). The findings sug-
gest that ETA receptor antagonists, which are already used in
the treatment of pulmonary hypertension (Palmer and Love,
2011), and potentially ETB receptor agonists, have therapeutic
potential in AD.
THE RENIN-ANGIOTENSIN SYSTEM IN ALZHEIMER’S
DISEASE
The renin-angiotensin system (RAS) plays an important role in
fluid homeostasis and regulation of blood pressure. ACE cat-
alyzes the conversion of angiotensin I (non-vasoactive) to the
vasoconstrictor, angiotensin II. ACE also cleaves and thereby inac-
tivates the vasodilator, bradykinin. These vasopressor activities
can be blocked either by ACE-inhibitors, a standard treatment for
hypertension or by Ang II receptor antagonists that inhibit Ang
II-mediated vasopressor effects. ACE is expressed by the endothe-
lium and neurons within the brain (Turner and Hooper, 2002;
Miners et al., 2008c).
The involvement of the RAS, particularly ACE, in the patho-
genesis of AD has been studied extensively (reviewed in Kehoe
et al., 2009). ACE cleaves Aβ in vitro (Hu et al., 2001; Hemming
and Selkoe, 2005; Oba et al., 2005; Sun et al., 2008; Toropygin
et al., 2008) and retards Aβ aggregation and neurotoxicity (Hu
et al., 2001). A recent study indicated that ACE-mediated cleavage
of Aβ1−42 resulted in the formation of the less neurotoxic Aβ1−40
species (Zou et al., 2007). The exact contribution of ACE to the
regulation of Aβ in vivo remains unclear (reviewed in Kehoe et al.,
2009). Eckman et al. (2006) reported that endogenous Aβ levels
were unchanged in an ACE knockout mouse and in mice treated
with ACE inhibitors. In support of the earlier studies, Hemming
et al. (2007) found that captopril did not significantly affect Aβ
levels in two human APP transgenic mouse lines. More recently,
however, Wang et al. (Zou et al., 2007) showed that administra-
tion of captopril for 7 or 11 months to 6-month old tg2576 mice
(transgenic for the Swedish double mutation in human APP) pro-
moted Aβ deposition. The divergence of results could reflect a
difference in the species and age of the animals used, and the
respective dosage regimes, and highlights the need for further
investigation.
ACE level and enzyme activity are increased within the cere-
bral cortex in AD. This has been demonstrated inmultiple human
post-mortem studies (Arregui et al., 1982; Barnes et al., 1991;
He et al., 2006; Miners et al., 2008a). We showed a strong cor-
relation between ACE activity and disease severity, as indicated
by Braak tangle stage and parenchymal Aβ load (Miners et al.,
2008a). Thus, ACE-mediated cleavage of Aβ is not impaired in
AD. We also showed that ACE protein level and activity were
upregulated in human neuronal SH-SY5Y cells in response to
exposure to synthetic, aggregated Aβ1−42 (Miners et al., 2008a)
suggesting that induction of ACE is a likely to be a physiological
response to increasing Aβ level and may help to prevent further
Aβ accumulation.
A common Alu (indel) insertion(I)/deletion(D) polymor-
phism (rs 1799752) in intron 16 of the ACE gene was reported to
be associated with sporadic AD, the greatest risk being associated
with homozygosity of the I allele (Kehoe et al., 1999). This was
confirmed in several meta-analyses (Narain et al., 2000; Kehoe
et al., 2003; Elkins et al., 2004; Lehmann et al., 2005) and was
supported to some extent by some of the earlier whole-genome
association studies (Li et al., 2008; Thornton-Wells et al., 2008)
although a number of more recent and larger studies have failed
to find any association. In the original studies, homozygosity of
the D and I alleles was associated with the highest and lowest ACE
protein level in the periphery, respectively, (Rigat et al., 1990)
although this association only partly explains the total variance
of ACE in the periphery (Terao et al., 2013). We found that the
ACE II genotype was associated with reduced ACE protein level in
the CSF (Miners et al., 2010b). Other studies showed significant
association between ACE variants and Aβ1−42 concentration or
the Aβ1−42:Aβ1−40 ratio in the CSF (Lehmann et al., 2005; Kauwe
et al., 2009). These studies suggested that an association between
the ACE polymorphism and AD might be mediated through
reduced ACE-mediated proteolysis of Aβ. However, on analy-
sis of post-mortem brain tissue, we subsequently found that the
putative AD risk genotype, ACE II, was associated with increased
rather than decreased ACE activity (Miners et al., 2010b). ACE
expression within the brain did not mirror findings in the plasma
and CSF; this finding is in keeping with other evidence that RAS
within the brain functions in isolation from the periphery. In
addition, ACE enzyme activity did not correlate with ACE protein
level, possibly due to the effects of post-translational modification
on ACE enzyme activity.
Although it now seems unlikely that ACE contributes sub-
stantially to the degradation of Aβ in vivo, there is evidence
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that the RAS influences several other processes that contribute
to the development of AD. Intracerebral infusion of Ang II
in male Sprague–Dawley rats resulted in significant cognitive
impairment, increased amyloid pathology [due to elevated β- and
γ-secretase activity (Zhu et al., 2011)] and an increased level
of phosphorylated tau (Tian et al., 2012). Ang II infusion also
resulted in stimulation of type 1 Ang II receptors (AT1Rs) that
mediate vasoconstriction. These effects were prevented by losar-
tan, an AT1R receptor antagonist. Additionally, Ang II inhibits
potassium-mediated release of ACh (Barnes et al., 1992), and
influences tumor necrosis factor-α and transforming growth fac-
tor β signaling (Hamdi and Castellon, 2004) and blood-brain
barrier maintenance (Wosik et al., 2007). Administration of the
Ang II receptor antagonist valsartan in tg2576 mice (transgenic
for the Swedish double mutation in human APP) resulted in
lower Aβ deposition and improved cognitive performance (Wang
et al., 2007). Danielyan and colleagues similarly showed that
intra-nasal administration of losartan significantly reduced Aβ
pathology (Danielyan et al., 2010). In view of these pleotropic
actions of Ang II, that are associated with a number of AD
pathological processes, and the recent observations in animal
models of AD treated with losartan, AT1Rs have come under
scrutiny as a potential therapeutic option for AD. Data from
large retrospective clinical studies (Li et al., 2010; Davies et al.,
2011) and secondary explorations of clinical trial studies (Gao
et al., 2013; O’Caoimh et al., 2014) suggest that use of ARBs
may be protective against the development and progression of
AD (reviewed in Ashby and Kehoe, 2013). The finding in some
studies that the reduction in risk is associated with ARBs but
not (or not to the same extent) with ACE inhibitors (Kehoe
et al., 2013) may reflect a beneficial effect of maintaining ACE-
mediated Aβ degradation. Clinical trials are underway to deter-
mine whether losartan (ISRCTN93682878) or perindopril vs.
telmisartan (NCT02085265) can reduce AD-associated pathology
and cognitive decline in mild to moderate AD.
Chronic exposure to elevated ACE activity may increase the
risk of dementia by promoting cerebrovascular disease. In a
large prospective cohort of patients (the SMART-MR study) with
symptomatic atherosclerotic disease, elevated serum ACE activ-
ity was associated with increased risk of ischemic stroke and high
blood pressure (Jochemsen et al., 2012a) and increased progres-
sion of white matter ischemic damage (Jochemsen et al., 2012b).
ACE expression is directly regulated by hypoxia via a HIF1-α-
dependent mechanism. Krick et al. (2005) observed increased
ACE expression in cultured human FBPA (advential fibroblasts)
that was dependent on HIF1-α expression. Upregulation of more
than one pathwaymay therefore account for increased production
of Ang II in dementia, including AD.
Emerging studies highlight possible interactions between the
ET-1 and RAS in AD. Ang II interacts with the ET system to
increase ET-1 production from endothelial cells (Dohi et al.,
1992) and vascular adventitial fibroblasts (An et al., 2006) via a
mechanism involving NADPH oxidase (An et al., 2007). Ang II
mediates the transcriptional regulation of the preproenothelin-1
(ppET-1) gene and induces the synthesis of ET-1 in vitro (Rossi
et al., 1999). Ang II was also shown to increase tissue ET-1 in vivo
(Moreau et al., 1997). In addition, ET-1 also contributes to the
vascular actions of Ang II (Balakrishnan et al., 1996;Moreau et al.,
1997) and ET-1 enhances the conversion of Ang I to Ang II in
pulmonary artery endothelial cells (Kawaguchi et al., 1991).
HYPOPERFUSION AND VASCULAR DYSFUNCTION IN
ALZHEIMER’S DISEASE
There is increasing evidence that vascular dysfunction, reduced
cerebral blood flow and AD are interdependent pathological pro-
cesses. In large epidemiological studies, cardiovascular risk factors
(diabetes, hypertension, high cholesterol levels, atherosclerosis,
obesity) have emerged as risk factors for AD (DeKosky et al.,
1990; Johnson et al., 2005; Ruitenberg et al., 2005; Mak et al.,
2012). Brain ischemia and stroke were reported to increase the
risk of dementia and AD (de la Torre, 2005; Dickstein et al., 2010).
Many AD patients have some degree of cerebrovascular pathol-
ogy including white matter ischemic lesions (Brun and Englund,
1986a,b; Englund et al., 1988; Englund and Brun, 1990; Ellis et al.,
1996; Kalaria, 2000) and most AD patients have CAA (Esiri and
Wilcock, 1986; Love et al., 2003; Jellinger and Attems, 2006). Brain
ischemia is the defining pathogenic process in most patients with
VaD but in AD cerebral blood flow is also usually reduced (Sharp
et al., 1986; Jagust et al., 1987; Schuff et al., 2009) and contributes
to cognitive impairment. Reduced cerebral blood flow proba-
bly anticipates the development of dementia in AD (Ruitenberg
et al., 2005), and occurs well before any pathological or neurolog-
ical abnormalities in mouse models of AD (Niwa et al., 2002a,b;
Iadecola, 2004).
There is evidence from some although not all studies (Chui
et al., 2012) that ischemia is not only an additive cause of brain
damage in AD but also contributes to the neurodegenerative dis-
ease processes. Transient brain ischemia resulting from cardiac
arrest was shown to cause a marked increase in serum Aβ1−42 in
humans (Zetterberg et al., 2011). Ischemia, or its in vitro simula-
tion by combined deprivation of oxygen and glucose, is associated
with increased production of Aβ in animal and cell culturemodels
of AD (Zhang et al., 2007; Guglielmotto et al., 2009; Zhiyou et al.,
2009). This probably reflects increased amyloidogenic processing
of APP by γ- and β-secretase in response to hypoxia (Sun et al.,
2006; Li et al., 2009), resulting in increased plaque formation
(Garcia-Alloza et al., 2011). HIF-1α is the primary sensor of tis-
sue hypoxia (Wenger, 2002). HIF-1α subunits are stabilized under
conditions of hypoxia, dimerize with HIF-1β and translocate to
the nucleus, where they associate with hypoxia-response elements
and bind transcriptional co-activators to induce the expression
of hypoxia-responsive genes. It is likely that Aβ also contributes
indirectly to the reduction in CBF, by mediating vasoconstriction
(Claassen and Zhang, 2011) (Figure 1).
We have reviewed (above) evidence that Aβ upregulates ET-1
and Ang II production. In addition, Aβ peptides were reported
to enhance the vasoconstrictor action of a thromboxane ana-
log (Niwa et al., 2001; Iadecola, 2003). In mouse models of AD,
Aβ impaired cerebral autoregulation and functional hyperemia
(Niwa et al., 2000, 2001, 2002a), although in studies to date, cere-
bral autoregulation has not been shown to be impaired in AD
(Claassen and Zhang, 2011). The Iadecola group showed that
oxidative stress plays a critical role in the attenuation of func-
tional hyperemia by Aβ1−40 (Park et al., 2004). The in vitro
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finding by Palmer et al. (2013) that an Aβ1−40 induced increase
in ET-1 production by endothelial cells could be blocked by
co-administration of the antioxidant superoxide dismutase sug-
gests that the attenuation of functional hyperemia by oxida-
tive stress may be partly mediated by ET-1. Cerebral ischemia
also induced tau phosphorylation, leading to the death of basal
forebrain cholinergic neurons which are profoundly depleted
in AD (Zheng et al., 2002; Li et al., 2011). Li et al. (2011)
reported that ET-1 exacerbated Aβ deposition, tau phosphoryla-
tion and cognitive impairment after intracerebral injection of Aβ
in rats.
POST-MORTEM ASSESSMENT OF CEREBRAL
HYPOPERFUSION
Evaluation of the possible contribution of ischemia to the devel-
opment or progression of AD and other neurological disorders
has been impaired by the lack of objective, quantifiable mark-
ers of hypoperfusion in post-mortem brain tissue. Pathologists
have relied on morphological assessment of paraffin sections,
and although this approach has been informative it is limited
by its subjectivity and relative insensitivity, relying on the iden-
tification of infarcts and regions of white matter rarefaction
rather thanmore subtle manifestations of ischemia. One potential
approach to quantifying ante-mortem hypoperfusion by exami-
nation of post-mortem brain tissue is the measurement of gene
transcripts and proteins involved in the molecular responses to
brain ischemia. As noted above, HIF-1α subunits are the prin-
cipal sensors of tissue hypoxia (Acker and Acker, 2004). Under
conditions of chronic or intermittent hypoxia there is an increase
in HIF-1α transcription (Nanduri et al., 2008; Powell, 2009).
Tissue hypoxia also causes upregulation of a large number of
other genes. Some, like VEGF and heme-oxygenase (HO-1), are
upregulated by HIFs (Liu et al., 1995; Shweiki et al., 1995; Pham
et al., 2002); others, such as neuroglobin are upregulated inde-
pendently of HIFs (Sun et al., 2001). Fernando et al. (2006)
reported elevated immunolabeling of astrocytes or microglia for
HIF-1α and HIF-2α within deep white matter lesions in the
elderly. We measured VEGF by ELISA, in both cerebral cortex
and white matter (Barker et al., 2013) from human post-mortem
brains, and found it to be elevated in the cerebral cortex in AD
independently of the severity of small vessel disease or CAA.
VEGF was not elevated in the white matter in AD (Barker et al.,
2014).
In a study of two independent post-mortem cohorts, we
recently showed that the ratio of myelin-associated glycoprotein
(MAG) to proteolipid protein 1 (PLP1) in the white matter cor-
related inversely with the severity of small vessel disease, and so
presumably with the degree of ante-mortem ischemia (Barker
et al., 2013). Our rationale for measuring this combination of
myelin proteins was that the transport of myelin proteins from
the oligodendrocyte cell body where they are synthesized, to their
site of insertion in the myelin sheath, is an energy-dependent
process and MAG, being expressed only adaxonally, far from the
oligodendrocyte cell body, is more susceptible to ischemia than is
PLP, expressed throughout the myelin sheath. We have found that
MAG is also sensitive to ischemia in the gray matter and are cur-
rently using a combination of methods to assess the relationships
between the activity of the endothelin and RAS, cerebral hypop-
erfusion, neurodegenerative pathology and white matter ischemic
damage in AD and other dementias.
Our findings to date point toward different processes under-
lying ischemic changes in the cerebral cortex and white matter
in AD, VaD and dementia with Lewy bodies (DLB) (Figure 2).
Whereas ET-1 production is significantly increased in the cere-
bral cortex in AD, presumably reflecting locally elevated Aβ and
oxidative stress, it is reduced in the white matter, as would be
expected for a physiological adaptation to reduced blood flow.
It should be noted that multiple, topographically remote pro-
cesses are likely to contribute to white matter ischemia in AD.
These include meningeal and cortical CAA, Ang II- and ET1-
mediated constriction of perforating arterioles that traverse the
cortex to supply the white matter, and in some patients, systemic
processes such as postural hypotension (Ballard et al., 2000) and
atrial fibrillation (Ott et al., 1997).
There is little published information on the possible contribu-
tion of cerebral hypoperfusion to other dementias. Patients who
have DLB are particularly prone to neurocardiovascular insta-
bility (Ballard et al., 1998), which correlates with the severity of
white matter ischemic lesions detectable by MRI (Kenny et al.,
2004). Several other studies have demonstrated reduced perfu-
sion of the parieto-occpital cortex in DLB (Ishii et al., 1999;
Lobotesis et al., 2001; Colloby et al., 2002; Firbank et al., 2003;
Fong et al., 2011). We recently reported that hypoperfusion in
the occipital cortex of patients with DLB was associated with
reduced microvessel density (as determined by measuring the
level of factor VIII-related antigen) (Barker et al., 2014) and a
reduction in VEGF (Miners et al., 2014). The VEGF level in
DLB correlated positively with the ratio of MAG:PLP, in keep-
ing with a direct relationship between reduced VEGF, reduced
vascularity and hypoperfusion (leading to reduced MAG:PLP).
The mechanism of VEGF reduction in the occipital cortex in
FIGURE 2 | Divergent pathways responsible for cerebral hypoperfusion
in dementia. Our observations on human post-mortem brain tissue
suggest that (A) in AD, cerebral hypoperfusion is mediated in part by
elevated ECE-1/-2 and ACE in the cerebral cortex in AD in response to
accumulating Aβ, whereas (B) in DLB, cerebral hypoperfusion is mediated
by reduced vessel density in association with a reduction in VEGF
expression, possibly in response to α-syn accumulation mediated by
ischemia. In each pathway a vicious cycle ensues that accelerates disease
progression.
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DLB is unclear. However, it seems to be related to the under-
lying disease process, correlating negatively with the levels of
total α-syn and of α-syn phosphorylated at serine-129 (Figure 2).
VEGF level was reduced in SHSY-5Y cells overexpressing human
α-syn. Conversely, oxygen-glucose deprivation increased α-syn
level and aggregation. In contrast to AD, in DLB the level of
ET-1 and activity of ACE were similar to levels in age-matched
controls.
NEPRILYSIN AND CEREBRAL AMYLOID ANGIOPATHY
The most common form of CAA is caused by cerebrovascular
accumulation of Aβ in the walls of leptomeningeal and cerebro-
cortical blood vessels, particularly arterioles (Revesz et al., 2002,
2003). CAA increases in prevalence with age, to about 45% in
those over 80 years, and is present in over 90% of patients with
AD (Love et al., 2003). Aβ1−40 is the most abundant isoform
in vessel walls (Gravina et al., 1995). It is thought to be pre-
dominantly, if not exclusively, of neuronal origin (Calhoun et al.,
1999; Burgermeister et al., 2000; van Dorpe et al., 2000). The
Aβ accumulates initially in the basement membrane but eventu-
ally causes the death of the cerebrovascular smooth muscle cells
(CVSMCs) and replaces the tunica media. Particularly in larger
vessels, Aβmay also deposit in the adventitia (Weller et al., 2009a).
Cerebrovascular accumulation of Aβ may be caused by increased
production of this peptide, in familial forms of AD and CAA.
However, in most sporadic cases, decreased removal, particularly
as a result of the effects of age on vessel walls, is likely to be the
major cause of CAA. Arteriosclerosis and age-related changes to
the composition of the arterial basement membranes may impede
the perivascular drainage of Aβ, as does preexisting CAA (Weller
et al., 2009b; Hawkes et al., 2011).
Another determinant of the likelihood of vascular accumu-
lation of Aβ is the activity of Aβ-degrading proteases within
the tunica media. We and others showed that NEP is abun-
dantly expressed by smooth muscle cells within larger arterioles
in the cerebral cortex and leptomeninges (Carpentier et al., 2002;
Miners et al., 2006) in human brain tissue, and that the level
of NEP is reduced in AD patients with severe CAA. The reduc-
tion is not simply a consequence of the loss of smooth muscle
cells. We demonstrated that the reduction of NEP protein in CAA
affected both Aβ-laden and non-Aβ-laden vessels (Miners et al.,
2006). We also showed that NEP enzyme activity is reduced in
CAA, in both the leptomeninges (within which the only source of
NEP is the smooth muscle cells in the blood vessels) and vessel-
enriched preparations of cerebral cortex (Miners et al., 2011c).
The reduction in NEP activity was still evident after adjustment
for the smoothmuscle actin content of the samples and was there-
fore not simply a consequence of death of CVSMCs, although loss
of CVSMCs, whether from arteriosclerosis or as a consequence of
CAA, would be expected to exacerbate any preexisting deficiency
in vessel-associated NEP.
To model the role of NEP in CAA we manipulated NEP
activity in cultured human brain-derived vascular smooth mus-
cle cells, using siRNA knock-down of NEP, to reduce activity,
or transfection of NEP cDNA to enhance activity, and mea-
sured cell death after adding recombinant Aβ1−42 (Miners et al.,
2011c). We found that NEP protected against Aβ1−42-mediated
cell death. We also analyzed the influence of APOE geno-
type on vessel-associated NEP activity. The relationship between
APOE and vessel-associated NEP activity mirrored that between
APOE genotype and risk of AD and CAA: after adjustment
for smooth muscle actin, NEP activity was highest in blood
vessels from patients with APOE ε2/3 genotype and decreased
stepwise through APOE ε3/3, ε3/4, and ε4/4 genotypes. The pos-
sible contribution to CAA of changes in the activity of other
vessel-associated Aβ-degrading enzymes, including ECE-1 and
IDE (Morelli et al., 2004; Lynch et al., 2006) have yet to be
assessed.
CONCLUDING REMARKS
Multiple Aβ-degrading proteases are upregulated in AD in
response to the rising concentration of Aβ. This upregulation
probably mitigates the accumulation and toxicity of Aβ, includ-
ing in the context of CAA, but also enhances the degradation
of other substrates of these proteases. Those substrates include
the vasodilator bradykinin, and precursors of the potent vaso-
constrictors ET-1 and Ang II. The resulting vasoconstriction is
likely to contribute to reduced cerebral blood flow in AD and per-
haps also to the neurodegenerative disease process itself, through
increased production, accumulation and deposition of Aβ and
increased phosphorylation of tau. Reduced cerebral blood flow
also contributes to VaD and dementia with Lewy body dis-
eases but the distribution and mechanisms of hypoperfusion are
different from those in AD. Our findings underline the limita-
tions of highly reductionist approaches for assessing the actions
of multifunctional proteases, and the importance of validating
experimental findings by analysis of human brain tissue.
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